Brief: Innocare Pharma Announces Achievement Of Primary Endpoint In Phase 2B Study Of Orelabrutinib,
15/12/2025 12:23
Dec 15 (Reuters) - Zenas Biopharma Inc ZBIO.O: ZENAS BIOPHARMA’S PARTNER, INNOCARE PHARMA, ANNOUNCES ACHIEVEMENT OF PRIMARY ENDPOINT IN PHASE 2B STUDY OF ORELABRUTINIB, A BTK INHIBITOR, FOR SYSTEMIC LUPUS ERYTHEMATOSUS Source text: ID:nGNX9kQfyb Further company coverage: ZBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints